[Lipiwatch: a study of the treatment of dyslipidemias in Luxembourg].
LIPIWATCH is an observational study which has been initiated for 6 months in Belgium and in Luxembourg in 1997 to evaluate if patients treated by lipid-lowering drugs could reach the recommendations of the EAS and NCEP II for LDL-C. 76 patients (31 men) with a mean age of 59.2 +/- 11.39 years were included. 96% of patients had at least one other associated cardiovascular risk factor. After 6 months of treatment, 33% of all patients and only 30% of patients with coronary heart disease or peripheral vascular disease or at least 2 other risk factors reached the recommendations of the EAS. 25% of all patients and only 20% of patients with known coronary heart disease reached the NCEP II recommendations. 55% of patients had a statin prescribed and 38% a fibrate. Mean total cholesterol and mean LDL-C was lowered by 20% and 19% after 6 months. These disappointing results confirmed an insufficient awareness by physicians and patients, inadequate dosages of drugs and a bad compliance by patients.
Michel
G
G
Service d'endocrinologie-diabétologie, Centre Hospitalier Luxembourg.
Wirion
R
R
Keipes
M
M
Scharpantgen
R
R
Heger
G
G
D001530:Belgium; D003327:Coronary Disease / Q000150:complications; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008189:Luxembourg; D008297:Male; D008875:Middle Aged; D016491:Peripheral Vascular Diseases / Q000150:complications
D000960:Hypolipidemic Agents